$IMUX
Immunic Inc

2016 Q3 Form 10-Q Financial Statement

#000128077616000008 Filed on August 02, 2016

View on sec.gov

Income Statement

Concept 2016 Q3 2016 Q2 2015 Q2
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.770M $2.690M $3.530M
YoY Change 2.97% -23.8% 40.64%
% of Gross Profit
Research & Development $7.469M $6.858M $11.55M
YoY Change -22.57% -40.6% 26.52%
% of Gross Profit
Depreciation & Amortization $420.0K $490.0K $328.0K
YoY Change 29.23% 49.39% 33.33%
% of Gross Profit
Operating Expenses $10.24M $9.546M $15.08M
YoY Change -16.99% -36.69% 29.56%
Operating Profit -$10.24M -$9.546M -$15.08M
YoY Change -16.99% -36.69% 29.56%
Interest Expense $80.00K $80.00K $10.00K
YoY Change 700.0% 700.0% 0.0%
% of Operating Profit
Other Income/Expense, Net $61.00K $78.00K -$28.00K
YoY Change 74.29% -378.57% -101.9%
Pretax Income -$10.18M -$9.470M -$15.11M
YoY Change -17.24% -37.33% 48.57%
Income Tax
% Of Pretax Income
Net Earnings -$10.18M -$9.468M -$15.11M
YoY Change -17.25% -37.32% 48.58%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$12.89M -$12.14M -$25.18M
COMMON SHARES
Basic Shares Outstanding 31.54M shares 31.24M shares 24.01M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2016 Q3 2016 Q2 2015 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $68.10M $73.60M $71.90M
YoY Change 13.88% 2.36% -20.81%
Cash & Equivalents $68.09M $73.60M $71.95M
Short-Term Investments
Other Short-Term Assets $1.400M $1.800M $3.500M
YoY Change -51.72% -48.57% 34.62%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $69.46M $75.44M $75.45M
YoY Change 10.95% -0.01% -19.3%
LONG-TERM ASSETS
Property, Plant & Equipment $2.922M $3.014M $4.212M
YoY Change -29.81% -28.44% 29.04%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $87.00K $182.0K $214.0K
YoY Change -49.12% -14.95% -18.63%
Total Long-Term Assets $3.009M $3.196M $4.426M
YoY Change -30.57% -27.79% 25.49%
TOTAL ASSETS
Total Short-Term Assets $69.46M $75.44M $75.45M
Total Long-Term Assets $3.009M $3.196M $4.426M
Total Assets $72.47M $78.63M $79.87M
YoY Change 8.26% -1.55% -17.67%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.193M $887.0K $920.0K
YoY Change 117.3% -3.59% -37.03%
Accrued Expenses $3.357M $3.439M $8.852M
YoY Change -54.51% -61.15% 52.46%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $4.630M $4.473M $9.977M
YoY Change -42.97% -55.17% 31.95%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $100.0K $0.00 $159.0K
YoY Change -31.51% -100.0% -45.55%
Total Long-Term Liabilities $83.00K $12.00K $159.0K
YoY Change -43.15% -92.45% -45.55%
TOTAL LIABILITIES
Total Short-Term Liabilities $4.630M $4.473M $9.977M
Total Long-Term Liabilities $83.00K $12.00K $159.0K
Total Liabilities $4.713M $4.485M $10.14M
YoY Change -42.98% -55.75% 29.07%
SHAREHOLDERS EQUITY
Retained Earnings -$232.1M -$221.9M -$180.7M
YoY Change 20.26% 22.81% 45.63%
Common Stock $3.000K $56.00K $2.000K
YoY Change 50.0% 2700.0% 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $67.76M $74.15M $69.74M
YoY Change
Total Liabilities & Shareholders Equity $72.47M $78.63M $79.87M
YoY Change 8.26% -1.55% -17.67%

Cashflow Statement

Concept 2016 Q3 2016 Q2 2015 Q2
OPERATING ACTIVITIES
Net Income -$10.18M -$9.468M -$15.11M
YoY Change -17.25% -37.32% 48.58%
Depreciation, Depletion And Amortization $420.0K $490.0K $328.0K
YoY Change 29.23% 49.39% 33.33%
Cash From Operating Activities -$7.890M -$8.820M -$15.11M
YoY Change -34.47% -41.63% 52.94%
INVESTING ACTIVITIES
Capital Expenditures -$270.0K -$40.00K -$1.310M
YoY Change -12.9% -96.95% 445.83%
Acquisitions
YoY Change
Other Investing Activities $220.0K $80.00K $120.0K
YoY Change -35.29% -33.33% -152.17%
Cash From Investing Activities -$50.00K $40.00K -$1.190M
YoY Change -225.0% -103.36% 153.19%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 2.430M 4.510M 0.000
YoY Change -1378.95% -100.0%
NET CHANGE
Cash From Operating Activities -7.890M -8.820M -15.11M
Cash From Investing Activities -50.00K 40.00K -1.190M
Cash From Financing Activities 2.430M 4.510M 0.000
Net Change In Cash -5.510M -4.270M -16.30M
YoY Change -54.8% -73.8% -136.39%
FREE CASH FLOW
Cash From Operating Activities -$7.890M -$8.820M -$15.11M
Capital Expenditures -$270.0K -$40.00K -$1.310M
Free Cash Flow -$7.620M -$8.780M -$13.80M
YoY Change -35.04% -36.38% 43.15%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-62000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-360000 USD
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-125000 USD
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2016
dei Document Period End Date
DocumentPeriodEndDate
2016-06-30
dei Document Type
DocumentType
10-Q
dei Entity Central Index Key
EntityCentralIndexKey
0001280776
CY2016Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
31540861 shares
dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
dei Entity Registrant Name
EntityRegistrantName
VITAL THERAPIES INC
dei Trading Symbol
TradingSymbol
VTL
CY2015Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1221000 USD
CY2016Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
887000 USD
CY2015Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5271000 USD
CY2016Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3439000 USD
CY2015Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
8060000 USD
CY2016Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
8988000 USD
CY2015Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
80000 USD
CY2016Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
80000 USD
CY2015Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
285098000 USD
CY2016Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
295977000 USD
CY2015Q4 us-gaap Assets
Assets
89081000 USD
CY2016Q2 us-gaap Assets
Assets
78632000 USD
CY2015Q4 us-gaap Assets Current
AssetsCurrent
85088000 USD
CY2016Q2 us-gaap Assets Current
AssetsCurrent
75436000 USD
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
64000 USD
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
36000 USD
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
102238000 USD
CY2015Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
71946000 USD
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-1000 USD
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
135000 USD
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
8835000 USD
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
83416000 USD
CY2016Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
73598000 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-30292000 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-9818000 USD
CY2015Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
250646 shares
CY2016Q2 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
250539 shares
CY2015Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2016Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2016Q2 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
5261910 shares
CY2015Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2016Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2015Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
130000000 shares
CY2016Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
130000000 shares
CY2015Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
30473083 shares
CY2016Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
31539111 shares
CY2015Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
30473083 shares
CY2016Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
31539111 shares
CY2015Q4 us-gaap Common Stock Value
CommonStockValue
3000 USD
CY2016Q2 us-gaap Common Stock Value
CommonStockValue
3000 USD
CY2015Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-15107000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-29865000 USD
CY2016Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-9468000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-19057000 USD
CY2015Q4 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
140000 USD
CY2016Q2 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
147000 USD
CY2015Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
101000 USD
CY2016Q2 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
12000 USD
CY2015Q2 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
328000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
622000 USD
CY2016Q2 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
490000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
984000 USD
CY2015Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.63
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.25
CY2016Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.30
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.62
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents Continuing Operations
EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations
1000 USD
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents Continuing Operations
EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations
-1000 USD
CY2015Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2165000 USD
CY2016Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1339000 USD
CY2016Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
10100000 USD
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y5M27D
us-gaap Fair Value Assumptions Expected Dividend Rate
FairValueAssumptionsExpectedDividendRate
0
CY2015Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3533000 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6597000 USD
CY2016Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2688000 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5487000 USD
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-1797000 USD
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-76000 USD
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-83000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
921000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
478000 USD
us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
-175000 USD
us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
-294000 USD
CY2015Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
12000 USD
us-gaap Investment Income Interest
InvestmentIncomeInterest
23000 USD
CY2016Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
75000 USD
us-gaap Investment Income Interest
InvestmentIncomeInterest
135000 USD
CY2015Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
89081000 USD
CY2016Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
78632000 USD
CY2015Q4 us-gaap Liabilities Current
LiabilitiesCurrent
6655000 USD
CY2016Q2 us-gaap Liabilities Current
LiabilitiesCurrent
4473000 USD
CY2015Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
101000 USD
CY2016Q2 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
12000 USD
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-1805000 USD
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
131000 USD
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-28623000 USD
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-18783000 USD
CY2015Q2 us-gaap Net Income Loss
NetIncomeLoss
-15106000 USD
us-gaap Net Income Loss
NetIncomeLoss
-29864000 USD
CY2016Q2 us-gaap Net Income Loss
NetIncomeLoss
-9468000 USD
us-gaap Net Income Loss
NetIncomeLoss
-19057000 USD
CY2015Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-28000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
32000 USD
CY2016Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
78000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
145000 USD
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1 Segment
CY2015Q2 us-gaap Operating Expenses
OperatingExpenses
15078000 USD
us-gaap Operating Expenses
OperatingExpenses
29896000 USD
CY2016Q2 us-gaap Operating Expenses
OperatingExpenses
9546000 USD
us-gaap Operating Expenses
OperatingExpenses
19202000 USD
CY2015Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-15078000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-29896000 USD
CY2016Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-9546000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-19202000 USD
CY2015Q2 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
193000 USD
us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
418000 USD
CY2016Q2 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
226000 USD
us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
443000 USD
CY2015Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
431000 USD
CY2016Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
351000 USD
CY2015Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
184000 USD
CY2016Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
182000 USD
CY2015Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-1000 USD
CY2016Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
0 USD
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
0 USD
CY2015Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
163000 USD
CY2016Q2 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
147000 USD
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-2000 USD
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-1000 USD
CY2015Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-40000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
9000 USD
CY2016Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
3000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
10000 USD
CY2015Q4 us-gaap Payments For Commissions
PaymentsForCommissions
2100000 USD
us-gaap Payments For Commissions
PaymentsForCommissions
276000 USD
us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
51000 USD
us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
20000 USD
CY2015Q4 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
280000 USD
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
119000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1980000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
165000 USD
CY2015Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2016Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2015Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000 shares
CY2016Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000 shares
CY2015Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2016Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2015Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2016Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2015Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2016Q2 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2015Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1139000 USD
CY2016Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1599000 USD
CY2015Q4 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
32100000 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
8800000 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
8823000 USD
us-gaap Proceeds From Sale Of Machinery And Equipment
ProceedsFromSaleOfMachineryAndEquipment
0 USD
us-gaap Proceeds From Sale Of Machinery And Equipment
ProceedsFromSaleOfMachineryAndEquipment
2000 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
186000 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
32000 USD
CY2015Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
11869000 USD
CY2016Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
12002000 USD
CY2015Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3809000 USD
CY2016Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3014000 USD
CY2015Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
11545000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
23299000 USD
CY2016Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6858000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
13715000 USD
CY2015Q4 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
533000 USD
CY2016Q2 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
239000 USD
CY2015Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-202856000 USD
CY2016Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-221913000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
1801000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
2007000 USD
CY2016Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
206708 shares
CY2016Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
2827093 shares
CY2016Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
7.73
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
23583 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
13.81
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
1119824 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
16.60
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
5.81
CY2016Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
3376184 USD
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3716520 shares
CY2016Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4804663 shares
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
7.76
CY2016Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
7.85
CY2016Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
3315972 USD
CY2016Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
4675577 shares
CY2016Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
7.83
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
3.92
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
8.25
CY2016Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
2294523 USD
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y6M29D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y9M18D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
P7Y9M
CY2015Q4 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
5.50
CY2015Q4 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
6272727 shares
us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
1100000 shares
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
8098 shares
CY2015Q4 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
34500000 USD
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
9200000 USD
CY2015Q4 us-gaap Stockholders Equity
StockholdersEquity
82325000 USD
CY2016Q2 us-gaap Stockholders Equity
StockholdersEquity
74147000 USD
us-gaap Tangible Asset Impairment Charges
TangibleAssetImpairmentCharges
0 USD
CY2015Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
23996527 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
23984629 shares
CY2016Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
31247069 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
30905079 shares
CY2015Q4 vtl Accrued Clinical Costs
AccruedClinicalCosts
2675000 USD
CY2016Q2 vtl Accrued Clinical Costs
AccruedClinicalCosts
1749000 USD
vtl Cash Equivalents Investments Maturity Period
CashEquivalentsInvestmentsMaturityPeriod
P3M
vtl Change In Stock Option Early Exercise Repurchase Liability
ChangeInStockOptionEarlyExerciseRepurchaseLiability
52000 USD
vtl Change In Stock Option Early Exercise Repurchase Liability
ChangeInStockOptionEarlyExerciseRepurchaseLiability
23000 USD
vtl Common Stock Issuance Costs Included In Liabilities
CommonStockIssuanceCostsIncludedInLiabilities
141000 USD
vtl Common Stock Issuance Costs Included In Liabilities
CommonStockIssuanceCostsIncludedInLiabilities
4000 USD
vtl Fair Value Assets Between Hierarchy Levels Transfers Amount
FairValueAssetsBetweenHierarchyLevelsTransfersAmount
0 USD
CY2016Q2 vtl Maximum Aggregate Offering Price Of Securities
MaximumAggregateOfferingPriceOfSecurities
156300000 USD
CY2015Q2 vtl Maximum Aggregate Offering Price Of Securities
MaximumAggregateOfferingPriceOfSecurities
200000000 USD
CY2015Q4 vtl Maximum Aggregate Offering Price Of Securities
MaximumAggregateOfferingPriceOfSecurities
165500000 USD
CY2016Q2 vtl Maximum Amount Of Common Stock That Can Be Issued Under At The Market Sales Agreement
MaximumAmountOfCommonStockThatCanBeIssuedUnderAtTheMarketSalesAgreement
65800000 USD
CY2015Q2 vtl Maximum Amount Of Common Stock That Can Be Issued Under At The Market Sales Agreement
MaximumAmountOfCommonStockThatCanBeIssuedUnderAtTheMarketSalesAgreement
75000000 USD
CY2015Q4 vtl Maximum Amount Of Common Stock That Can Be Issued Under At The Market Sales Agreement
MaximumAmountOfCommonStockThatCanBeIssuedUnderAtTheMarketSalesAgreement
75000000 USD
CY2015Q2 vtl Maximum Number Of Common Shares That Can Be Issued By Certain Stockholders Under Shelf Registration Statement
MaximumNumberOfCommonSharesThatCanBeIssuedByCertainStockholdersUnderShelfRegistrationStatement
2500000 shares
us-gaap Use Of Estimates
UseOfEstimates
<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-top:8px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of financial statements in conformity with GAAP requires us to make certain estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Actual results could differ materially from those estimates and assumptions.</font></div></div>

Files In Submission

Name View Source Status
0001280776-16-000008-index-headers.html Edgar Link pending
0001280776-16-000008-index.html Edgar Link pending
0001280776-16-000008.txt Edgar Link pending
0001280776-16-000008-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
vtl-063016xexhibit311.htm Edgar Link pending
vtl-063016xexhibit312.htm Edgar Link pending
vtl-063016xexhibit321.htm Edgar Link pending
vtl-063016xexhibit322.htm Edgar Link pending
vtl-20160630.xml Edgar Link completed
vtl-20160630.xsd Edgar Link pending
vtl-20160630_cal.xml Edgar Link unprocessable
vtl-20160630_def.xml Edgar Link unprocessable
vtl-20160630_lab.xml Edgar Link unprocessable
vtl-20160630_pre.xml Edgar Link unprocessable
vtl-63016x10q.htm Edgar Link pending